Eisai/Biogen’s Lecanemab Effective Across Endpoints, But Will Safety Limit Use?

CTAD Presentation Is First Detailed Data

Alzheimer’s patients treated with the amyloid protofibril-clearing antibody had slower disease progression compared to placebo, with differences increasing over time. Safety concerns, however, are growing. 

Alzheimer's disease on MRI
Amyloid-related imaging abnormalities were among the most common adverse events • Source: Shutterstock

Detailed results from the Phase III Clarity AD clinical trial of Eisai Co., Ltd./Biogen, Inc.’s lecanemab in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild AD showed slower cognitive and functional declines over time, but concerns have emerged about deaths from brain hemorrhages, particularly in people on anticoagulants.

The Clarity AD results, presented on 29 November at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Francisco and simultaneously published in the New England Journal of Medicine,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By 

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.